Patiromer: A Review in Hyperkalaemia.

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hyperkalemia is a common complication in patients with chronic kidney disease (CKD), particularly those on renin-angiotensin-aldosterone system inhibitors (RAASis).
• Managing hyperkalemia is crucial to prevent cardiovascular complications and enable optimal RAASi therapy, which is vital for CKD management.

Purpose of the Study:

• To evaluate the efficacy and safety of patiromer, a novel potassium binder, in treating hyperkalemia in patients with CKD.
• To assess the ability of patiromer to maintain serum potassium reduction and facilitate continued RAASi use.

Main Methods:

• Two clinical trials (OPAL-HK and AMETHYST-DN) involving patients with CKD and hyperkalemia were conducted.
• Patients received oral patiromer, and its effects on serum potassium levels, tolerability, and ability to maintain RAASi therapy were assessed over various time points up to 52 weeks.

Main Results:

• Patiromer significantly reduced serum potassium levels from baseline in both trials.
• Continued patiromer therapy effectively maintained normokalemia and reduced hyperkalemia recurrence compared to placebo.
• Patiromer facilitated sustained RAASi therapy in a majority of patients, with a favorable safety profile including mild constipation and hypomagnesemia as common side effects.

Conclusions:

• Oral patiromer is an effective and well-tolerated treatment option for managing hyperkalemia in patients with CKD.
• Patiromer offers a valuable therapeutic strategy to normalize potassium levels and support the use of RAASis in this patient population.